Brief: Sun Pharma To Present Long-Term Follow-Up Data On Unloxcyt
BRIEF-Sun Pharma To Present Long-Term Follow-Up Data On Unloxcyt May 26 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMA - TO PRESENT LONG-TERM FOLLOW-UP DATA ON UNLOXCYT
SUN PHARMA - NEARLY 27% OF PATIENTS EXPERIENCED A COMPLETE RESPONSE
SUN PHARMA - ONLY 1 PATIENT EXPERIENCED A GRADE >3 IMMUNE-RELATED ADVERSE EVENT
Source text: ID:nBSE6Jx299
Further company coverage: SUN.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses